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The risk of clinical progression for human immunodeficiency virus (HIV)– infected persons
receiving treatment with highly active antiretroviral therapy (HAART) is poorly defined.
From an inception cohort of 8457 HIV-infected persons, 2027 patients who started HAART
during prospective follow-up were examined. Results were validated in another 2 groups of
patients (n ¼ 1946 and n ¼ 1442). In total, 200 patients (9.9%) experienced clinical progression
during 5177 person-years (incidence, 3.9/100 years). The most recently measured CD4 cell
count, virus load, and hemoglobin level all were independently related to the risk of clinical pro-
gression, as was a diagnosis of severe AIDS before the start of HAART. On the basis of these find-
ings, a scoring system was derived (range, 0–17). A single unit increase in the score was associ-
ated with a 38% increased risk of clinical progression (relative hazard, 1.38; 95% confidence
interval, 1.33–1.43; P < .0001). The scoring system was validated with remarkably good agree-
ment in the 2 other cohorts. This system can be used in patient and resource management.
The mortality and morbidity of human immunodeficiency
virus (HIV)–infected persons has improved dramatically in
recent years as a consequence of the widespread use of combi-
nation antiretroviral therapy—frequently termed highly active
antiretroviral therapy (HAART) [1–4]. With HAART, the risk
of death is estimated to be.85% lower than in the period before
HAART [1], although the incidence remains at 2–4 cases per
100 person-years of follow-up (PYFU) and, thus, is substantially
higher than for age-matched noninfected persons [1]. The
suggested therapeutic goal of HAART is to completely inhibit
viral replication and, hence, to eliminate the risk of developing
resistance [5]. Randomized trials assessing the efficacy of an-
tiretroviral drug combinations as part of HAART are using the
HIV load in plasma as a primary end point [6–9]. Furthermore,
changes in virus load during the course of therapy are now seen
as the key parameter for evaluating the response to HAART
and for determining the need for change of therapy [5]. Although
changes in virus load are clearly associated with the subsequent
clinical response in patients receiving HAART [10–15], the
roles of other laboratory markers, such as CD4 cell count and
hemoglobin levels, have been investigated less frequently.
Before the HAART era, several scoring systems were devel-
oped primarily to determine prognostic factors for survival after
the first AIDS diagnosis [16–19]. Clinical and laboratory mar-
kers or a combination were used to derive such systems. More
recently, most analyses demonstrating an association between
virus load and clinical progression also used fixed values of vi-
rus load at some arbitrary baseline [10, 11, 13, 15]. However,
because HAART can reverse many of the pathologic processes
induced by HIV [20–22], the most recently measured laboratory
values should be used to determine prognosis. A scoring system
that uses surrogate markers that predict the clinical prognosis of
patients on HAART would be useful in ongoing and future ran-
domized trials and as part of the prognostic evaluation and man-
agement of individual patients. The aims of the present study
were to develop a scoring system that takes into account the
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changes over time in the prognosis of individual patients in a
large cohort of prospectively followed patients who started
HAART and to validate the findings in other patient cohorts.
Patients and Methods
Patients. The EuroSIDA study is a prospective European study
of 8457 HIV-infected patients from 4 cohorts from 60 centers in
Europe and Israel. Study details have been published elsewhere
[23]. Patients were >16 years old at enrollment. Information was
collected from patient case notes onto a standardized data collection
form at baseline and every 6 months thereafter (a 6-month calendar
period is defined as 1 follow-up). At each follow-up, CD4 cell
counts and virus loads are measured. For each patient, the date of
starting and stopping each antiretroviral drug is recorded, as is the
use of drugs for prophylaxis against opportunistic infections. Dates
of diagnosis of all AIDS-defining diseases are also recorded accord-
ing to the 1993 Centers for Disease Control and Prevention clinical
definition of AIDS [24]. Members of the coordinating office visit
all centers periodically to ensure correct patient selection and accu-
rate data collection. Follow-up is to February 2001. We have
information available from up to 13 follow-up forms from cohort I
(identified in 1994), up to 10 follow-up forms for cohort II (iden-
tified in 1995–1996), 7 follow-up forms for cohort III (identified in
1997), and 2 follow-up forms for cohort IV (identified in 1999).
The score was derived from a cohort of EuroSIDA study patients.
The requirements for inclusion in the derivation cohort were defined
so that the impact of the whole course of HAART could be evaluated.
Patients had to have started a protease inhibitor (PI) or non-
nucleoside reverse-transcriptase inhibitor (NNRTI) for the first
time during prospective follow-up in the EuroSIDA study, the
PI/NNRTI had to be a part of a HAART antiretroviral regimen (i.e.,
>3 antiretroviral drugs in total), and patients had to have CD4 cell
counts and virus loads measured during the 6 months before starting
HAART (median time before HAART, 1 month for both CD4 cell
count and virus load) and >1 measurement of both markers after
starting HAART. In all, 2027 people fulfilled the eligibility criteria.
The scoring system was validated on 2 different data sets, to
ascertain how well the score predicted clinical progression among
other patient groups (validation cohorts). The first validation was
done for 1946 patients from the EuroSIDA cohort who started
HAART before recruitment to the EuroSIDA study. The second
validation was done for a cohort of 1442 patients from a single clinic
in Barcelona, all of whom started HAART. These patients were
identified from a clinical database in use at the hospital in which all
HIV-related information is prospectively collected [25]. The cohort
was initiated in 1985 and has enrolled 4291 patients. With regular
intervals, the cohort is validated by crossing the patients with
regional and national registries that detail mortality status and the
occurrence of new AIDS-defining events.
Methods. Patient characteristics were compared by using x2
tests for categorical variables and nonparametric Wilcoxon and
Kruskal-Wallis methods for continuous variables. Patient follow-
up began at the start date of HAART (or, for the EuroSIDA vali-
dation cohort, at the time of enrollment in EuroSIDA) and ended at
the first clinical progression (i.e., diagnosis of a new AIDS-defining
event or death) or was censored at the last clinical follow-up for
patients who did not progress.
Cox proportional hazards models were used to determine the fac-
tors associated with clinical progression. Initially, CD4 cell count,
virus load, hemoglobin level, and weight were included in a Cox
proportional hazards model as continuous time-updated variables.
Clinical status also was included as a fixed categorical variable at
start of HAART; the categories used were no AIDS, AIDS within
the past 12 months of start of HAART (all diagnoses except pro-
gressive multifocal leukoencephalopathy [PML] and non-Hodgkin
lymphoma [NHL]), and severe AIDS (PML and NHL). This stratifi-
cation was decided on before commencing the analysis and was
based on previous reports [17, 26]. CD4 cell count and virus load
were initially log-transformed to obtain the best fitting model.
Weight fitted as a time-updated continuous variable was not inde-
pendently prognostic and was removed from this first model.
As the next stage, other variables were added to this basic model to
see whether they provided additional prognostic information.
Demographic variables included region of Europe, sex, risk group,
race, age, and calendar quartile of the start of HAART. Treatment
variables included whether the patient was treatment naive at start
of HAART, time receiving nucleoside therapy before starting
HAART, the number of new nucleosides added, and whether the
regimen included a PI. Other variables included CD4 cell count
nadir, maximum virus load before starting HAART, baseline values
of weight, hemoglobin level, virus load, CD4 cell count, and changes
in these variables from baseline (as time-dependent covariates). The
use of disease-specific prophylaxis for opportunistic infections was
considered to see whether results differed if patients not receiving
prophylaxis when the CD4 cell count was low were excluded.
A final Cox model was constructed by using CD4 cell count, virus
load, and hemoglobin level, which were modeled as time-dependent
categorical variables. Categories of hemoglobin level and anemia
were derived from EuroSIDA study data published elsewhere [27].
Normal hemoglobin level was defined as .14 g/dL for men and
12 g/dL for women, mild anemia was defined as 8–14 g/dL for
men and 8–12 g/dL for women, and severe anemia was defined as
,8 g/dL for both men and women. Commonly reported cutoffs of
50 cells/mm3 and 200 cells/mm3 for CD4 cell count and 500 and
10,000 HIV RNA copies/mL for virus load were applied (and were
decided on before commencing the analysis). The natural loga-
rithms of the relative hazards (RHs), with rounding, were used to
derive a patient’s score, which increased or decreased as new labora-
tory values became available. The incidence of clinical disease pro-
gression was calculated for each score and also was modeled in a
Cox proportional hazards model as a time-dependent covariate to
derive the RH associated with a 1 point increase in the score. The
scoring system was validated on 2 validation cohorts. All analyses
were made with SAS software (version 6.12; SAS Institute).
Results
Table 1 describes the 2027 patients who satisfied the inclusion
criteria in the derivation cohort. The median age was 37 years.
Medians of other values at the start of HAART were as follows:
CD4 cell count, 244 cells/mm3 (interquartile range [IQR], 134–
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357 cells/mm3); virus load, 4.3 log HIV RNA copies/mL (IQR,
3.5–4.9 log HIV RNA copies/mL); length of follow-up, 33
months (IQR, 20–41 months); and calendar time at the initiation
of HAART, August 1997 (IQR, March 1997–June 1998). The
patients were heterogeneous, and there were differences be-
tween demographic groups in terms of CD4 cell count and virus
load at the start of HAART and in the proportions of patients
who were antiretroviral naive at the start of HAART, those who
started HAART with>3 new antiretrovirals to which they were
previously naive, and those who used a PI-based HAART rather
than an NNRTI-based HAART. In all, 450 (22%) had a history
of >1 AIDS-defining event: the most common were Pneumo-
cystis carinii pneumonia (110 [24%]), esophageal candidiasis
(104 [23%]), and Kaposi’s sarcoma (74 [16%]).
At the time of the analysis cutoff date (February 2001), 200
patients (9.9%) had experienced clinical events since the
initiation of HAART (i.e., they had progressed). Of these, 59
(30%) died, 94 (47%) had a first AIDS-defining illness, and
47 (24%) who had >1 AIDS-defining event before starting
HAART progressed to a new AIDS-defining event. By 12
months after the start of HAART, 5.1% of patients (95% confi-
dence interval [CI], 4.1%–6.1%) are estimated to have pro-
gressed to a new AIDS-defining event or died, 8.1% (95% CI,
6.8%–9.4%) had done so by 24 months, and 11.6% (95% CI,
10.0%–13.2%) had done so by 36 months. The most common
AIDS-defining events that defined clinical progression were
NHL (n ¼ 26), esophageal candida (n ¼ 21), pulmonary tuber-
culosis (n ¼ 14), Kaposi’s sarcoma (n ¼ 11), HIV wasting syn-
drome (n ¼ 9), and P. carinii pneumonia (n ¼ 7). Among the
patients who died, the cause of death was unknown for 23, an
opportunistic infection for 1, Kaposi’s sarcoma for 1, lymphoma
for 3, AIDS dementia for 1, wasting for 3, bacterial infections for
5, suicide for 1, and 21 other causes, including myocardial
infarctions, anemia, cancers, and liver-related deaths. For all
the fatal cases associated with AIDS-defining events, the events
were initially diagnosed before the start of HAART.
Table 1. Characteristics of 2027 patients starting highly active antiretroviral therapy (HAART).
Characteristic
No. (%) of
subjects
CD4 cell counts at
HAART, cells/mm3
Log10 virus load at
HAART, HIV RNA
copies/mL ARV naive >3 New ARVs PI HAART
Median P Median P % P % P % P
Sex
Male 1548 (76) 244 .16 4.3 ,.001 21 .08 43 .15 86 .47
Female 479 (24) 246 4.0 17 39 87
Risk
Homosexual 880 (43) 261 .002 4.3 .002 22 .06 44 .6 84 .08
IDU 511 (25) 209 4.3 18 41 87
Heterosexual 510 (25) 249 4.3 18 42 89
Other 126 (6) 227 4.1 16 38 83
Race
White 1771 (87) 243 .6 4.30 .8 19 ,.001 47 .08 86 .36
Other 256 (13) 250 4.30 29 42 84
Region of Europe
Southern 679 (34) 272 ,.001 4.2 ,.001 15 ,.001 37 ,.001 89 .002
Central 562 (28) 252 4.2 14 34 85
Northern 757 (37) 215 4.5 27 52 84
Eastern 29 (1) 280 4.4 62 79 69
Cohort
I 639 (32) 235 ,.001 4.3 .43 11 ,.001 33 ,.001 87 .001
II 481 (24) 209 4.3 10 32 93
III 828 (41) 260 4.3 28 51 83
IV 79 (4) 319 4.4 70 84 70
AIDS at HAART
No 1577 (78) 263 ,.001 4.2 ,.001 21 .05 44 .009 85 .07
Yes 450 (22) 136 4.6 17 37 88
Date started HAART, month/year
Before 1/97 272 (13) 118 ,0.001 4.6 ,0.001 7 ,0.001 16 ,0.001 99 ,0.001
1/97–1/98 986 (49) 241 4.4 21 41 96
1/98–1/99 434 (21) 289 3.9 16 46 75
1/99–1/00 252 (12) 291 4.2 35 63 63
After 1/00 83 (4) 280 4.2 22 65 51
Total 2027 (100) 244 4.3 20 42.0 86
NOTE. Kruskal-Wallis (for .2 groups) test and Wilcoxon (2 groups) tests were used to compare groups. ARV, antiretroviral agent; HIV, human immunodefi-
ciency virus; IDU, injection drug user; PI, protease inhibitor.
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Over the median 33 months of follow-up, CD4 cell counts
were measured a median of 11 times (IQR, 7–15 times), with a
median frequency of 1 time per 2.7 months (22,574 measures in
total). Virus load was measured a median of 10 times (IQR,
6–14 times; median frequency, 1 time per 2.9 months [21,780
measures in total]). Hemoglobin level was measured a median
of 6 times (IQR, 4–8 times; 1 time per 5.2 months [11,497
measures in all]). For those with a clinical event during follow-
up, the median lag time from the last CD4 cell count to the
event was 2 months (IQR, 1–4 months). For virus load, the cor-
responding median value was also 2 months (IQR, 1–4 months),
and for hemoglobin level it was 4 months (IQR, 2–7 months).
Of the factors assessed, 4 satisfied the requirement of being
independently associated with the risk of clinical progression
(see Patients and Methods): the most recently measurement of
CD4 cell count, virus load, and hemoglobin level and the clinical
status at the start of HAART. Table 2 shows the estimates of the
association between each of these variables and the RH of clini-
cal progression. Of note, the category of severe AIDS-defining
illnesses was associated with an RH of 2.14 (95% CI, 1.05–
4.36; P ¼ :036) in the initial Cox model, in which variables
were selected for inclusion in the score system (that model dif-
fered slightly from the model shown in table 2, because labora-
tory variables were included as continuous variables, not cat-
egories). Three equally sized groups of each laboratory marker
were created by use of all markers measured during follow-up.
Comparison of the highest third to the lowest third for each lab-
oratory marker revealed that CD4 cell count was the strongest
prognostic marker (RH, 4.52), followed by hemoglobin level
(RH, 3.31) and virus load (RH, 1.88). From this and the results
shown in table 2, it can be seen that the latest virus load added
relatively little, although statistically significant, extra prog-
nostic value.
We also investigated how these values changed when, instead
of using the current marker values, those obtained 3, 6, 9, or 12
months previously were used. The RHs for CD4 cell count were
4.66, 4.37, 3.46, and 3.11, respectively; for hemoglobin level,
the corresponding values were 3.24, 2.33, 2.04, and 1.53; and
for virus load, the corresponding values were 1.89, 1.79, 2.25,
and 2.20.
Scoring system. The RHs in table 2, based on the current
marker values, were used to derive a simple score by multiplying
the logarithms (base e) of the RHs in table 2 by 3 (thus, the value
for the lowest score component is 1—the choice of this multiply-
ing factor does not influence the predictive value of the score)
and rounding to the nearest whole number. By our method,
CD4 cell counts.200, 51–200, and<50 cells/mm3 were scored
as 0, 3, and 7, respectively; virus loads of,500, 500–999, and
>1000 HIV RNA copies/mL were scored as 0, 1, and 2, respec-
tively; hemoglobin levels that were normal or represented mild
or severe anemia were scored as 0, 2, and 6, respectively; no pre-
vious severe AIDS diagnosis was scored as 0; and severe AIDS
ever (NHL/PML) was scored as 2. By this method, a male patient
receiving HAART with a CD4 cell count of 100 cells/mm3, a
virus load of 7000 HIV RNA copies/mL, and a hemoglobin
level of 10 mg/dL (i.e., mild anemia) who had Kaposi’s sarcoma
diagnosed 18 months before starting HAART would have a
score of 6: 3 (CD4 cellsÞ þ 1 ðvirus loadÞ þ 2 ðmild anemiaÞ þ
0 ðno previous severe AIDS diagnosisÞ ¼ 6.
Risk of clinical disease by score: derivation cohort. The
median score at the start of HAART was 2 (IQR, 0–5); only 1%
of patients had a score>9 at the start of HAART (table 3). The
overall incidence of clinical disease was 3.9/100 person-years.
Table 4 shows the incidence of clinical progression for each
value of the score; scores>12 were combined because of limited
PYFU. A patient’s score could increase or decrease as new lab-
oratory marker values became available. In a Cox model in
which the score was fitted as a continuous covariate, there was,
on average, a 38% (95% CI, 33%–43%) higher risk of disease
per 1 unit of higher score. This indicates that the latest value of
the score strongly predicts the risk of clinical disease over the
next few months (i.e., the typical between visit interval). We
also evaluated the ability of the score to discriminate risk of
clinical disease over a longer period (12 months) by defining a
patient’s current clinical status as the one noted 12 months ear-
lier. As would be expected, the score was less discriminatory
(RH/1 unit, 1.29; P , :0001) but was still highly predictive of
outcome.
We considered whether the predictive value of the score
appeared to change over time by fitting an interaction term with
Table 2. Multivariate relative hazards (RHs) of clinical progression,
by Cox proportioned hazards model.
Parameter RH 95% CI P
Latest CD4 cell count, cells/mm3
.200 1.0 — —
51–200 2.6 1.8–3.6 ,.0001
<50 9.3 6.1–14.0 ,.0001
Latest virus load, HIV RNA copies/mL
,500 1.0 — —
500–9,999 1.3 0.9–2.0 .14
>10,000 1.8 1.3–2.5 .001
Hemoglobin level
Normal 1.0 — —
Mild anemia 2.2 1.6–2.9 ,.0001
Severe anemia 7.1 2.5–20.1 .0002
Clinical statusa
No new AIDS diagnosis 1.0 — —
AIDS in last 12 months (except NHL/PML) 0.9 0.5–1.4 .85
Severe AIDS ever (NHL/PML) 1.9 0.9–4.0 .07
NOTE. Laboratory markers were included as time-dependent categorical
variables. CI, confidence interval; HAART, highly active antiretrovial therapy;
HIV, human immunodeficiency virus; NHL, non-Hodgkin’s lymphoma; PML,
progressive multifocal leukoencephalopathy.
a Clinical status at the time of starting HAART was modeled as 3 categories:
category 1, no current AIDS diagnosis (i.e., never had AIDS or an AIDS diagno-
sis other than PML or NHL) .12 months before starting HAART; category 2,
had an AIDS diagnosis other than PML or NHL in past 12 months; category 3,
ever been diagnosed with PML or NHL.
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calendar time, but there was no significant evidence for such a
phenomenon.Similarly, therewasnoevidence that thepredictive
value of the score differed by duration of HAART. The predictive
value of the score was also similar when we excluded from
follow-up people whose CD4 cell count was ,200 cells/mm3
and for whom P. carinii prophylaxis was not being used.
Validation cohorts. In general, the characteristics of the 2
validation cohorts were similar to those of the derivation cohort
(table 3). There was a higher proportion of injection drug users
in the Barcelona validation cohort and a considerably lower
median CD4 cell count at the start of HAART among patients
from the EuroSIDA validation cohort. The median calendar
date of initiation of HAART was December 1996 (IQR, August
1996–July 1997) for the EuroSIDA validation cohort and July
1997 (IQR, February 1997–April 1998) for the Barcelona vali-
dation cohort. The median score at the start of HAART was 2 in
the EuroSIDA validation cohort (IQR, 0–5) and 2 in the
Barcelona validation cohort (IQR, 0–5). The overall incidence
of clinical progression was 3.9, 4.2, and 4.6 per 100 person-
years for the EuroSIDA derivation cohort, EuroSIDA validation
cohort, and the Barcelona validation cohort, respectively.
As shown in table 4, the 95% CIs around the incidence rates of
clinical progression at specific scores within each cohort were
wide, because of the limited follow-up in some cases. Although
there was some variation between the cohorts in the incidence
of clinical events, there was, in general, a high level of agree-
ment and a similar pattern of increasing incidence of clinical
events as the score increased. Estimates of the increased risk of
clinical progression associated with a single point increase in
the score from both Poisson regression and from Cox pro-
portional hazards models show a good agreement between the
derivation and both validation cohorts. In general, a single point
increase in score was associated with an increased risk of clinical
progression of 40% (table 4).
Figure1shows the increasing incidence ofclinical progression
and increasing scores for all 3 cohorts combined. At a score of
zero, the incidence rate of clinical progression was 1.0/100
PYFU (95% CI, 0.7–1.3/100 PYFU); this increased to 12.0/100
PYFU at a score of 6 (95% CI, 7.8–16.2/100 PYFU) and
142.9/100 PYFU at scores of >12 (95% CI, 54.3–231.4/100
PYFU). We repeated the analysis of the incidence of clinical pro-
gression separately for AIDS-defining illnesses and deaths. In the
combined 3 cohorts, there was comparable increase in the risk of
either of those 2 end points for each unit increase in the score
(42% [95% CI, 39%–46%] and 43% [95% CI, 37%–48%]),
respectively, by Poisson regression. Furthermore, there were
comparable increases in the risk of clinical progression associ-
ated with a 1 unit increase in the score between patients of white
or other races, sex, PI or NNRTI HAART regimens, and between
those who started HAART with a high or low score.
Discussion
We derived and independently validated a clinically prognos-
tic scoring system for assessing the incidence of clinical disease
progression among patients receiving HAART according to
their current clinical status. The derived score was based on the
latest information for 4 laboratory and clinical variables that
were highly predictive of clinical progression. These were the
only factors that independently predicted disease progression in
Table 3. Characteristics of 3 patient cohorts: derivation and validation cohorts.
Variables
EuroSIDA
derivation cohort
(n = 2027)
EuroSIDA
validation cohort
(n = 1946)
Barcelona
validation cohort
(n = 1442 )
Demographic characteristics, no. (%)
of patients
Male 1548 (76) 1597 (82) 1032 (72)
Homosexual 880 (43) 1044 (54) 409 (30)
IDU 511 (25) 320 (16) 527 (38)
AIDS at start of HAART 450 (22) 683 (35) 222 (15)
CD4 cell count at HAART,
median cells/mm3 (IQR) 244 (134–357) 166 (70–294)a 221 (100–354)
Virus load at HAART, median
HIV RNA copies/mL (IQR) 4.3 (3.5–4.9) 4.7 (4.0–5.3)b 4.61 (3.87–5.23)
Duration of follow-up, median months (IQR) 33 (20–41) 27 (13–42) 16 (10–18)
Age at HAART, median years (IQR) 37 (33–44) 37 (32–44) 32.0 (29.0–38.0)
Score at HAART, median (IQR) 2 (0–5) 2 (0–5)c 2 (0–5)
Clinical Events, no. (%) 200 (10) 183 (9) 77 (5)
PYFU 5173 4241 1682
Incidence (95% CI) 3.9 (3.4–4.4) 4.2 (3.6–4.8) 4.6 (4.0–5.2)
NOTE. “At HAART” is at the start of HAART (highly active antiretroviral therapy). CI, confidence interval; HIV,
human immunodeficiency virus; IDU, injection drug user; IQR, interquartile range; PYFU, person-years of follow-up.
a n ¼ 1304.
b n ¼ 1119.
c n ¼ 955.
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the derivation patient cohort. The predictive ability of the score
was validated in 2 other cohorts with a high degree of precision;
the relative risk of disease progression per 1 additional score
point in the 3 cohorts was40%. This score is important because
it provides the link between what can be regularly monitored and
what is most clinically important—that is, the risk of overt clini-
cal disease.
Our approach of using data that reflect a patient’s current
clinical status is most relevant to clinical practice. For a patient
with a given score value, the incidence rate shown in figure 1 is
the one that would be expected to apply over the ensuing 3
months, the period over which clinic visits tend to be spaced.
However, prediction over a longer period also would be useful.
We found that the score does indeed discriminate among patients
in regard to their risk of clinical disease for a 1-year period.
Many studies over the past 4 years have verified the indepen-
dent prognostic role of absolute level and changes in virus load
in response to antiretroviral therapy [10–15, 28–36], although
a meta-analysis of 15 trials showed some variability in the con-
sistency of this association [37]. In some studies, virus load was
the strongest marker for prognosis [10, 32], whereas others
suggested that virus load was a weak predictor in patients with
advanced immunodeficiency [31, 35]. Many studies assessed
patients receiving various nucleoside analogue therapies before
the era of HAART and thus are not directly applicable to patients
receiving HAART. Our data are not inconsistent with this body
of evidence but emphasize that, in a setting in which laboratory
marker values are updated as new measures are taken, the
additional prognostic information provided by virus load is com-
paratively small after adjustment for other prognostic variables,
such as CD4 cell count and hemoglobin level. Of note, most
virus load measurements in EuroSIDA are determined by the
Roche Amplicor system (64% of the sites uses this technique),
but other less frequently used systems (e.g., the Chiron branched
DNA system) may result in slightly lower readings of some spec-
imens. If the latter system is used, clinicians should be aware that
a person with a virus load of just below a cutoff point (i.e., 500 or
10,000 HIV RNA copies/mL) may have a value above the cutoff
if the virus load were remeasured by the Roche assay. Such per-
sons should be considered as potentially having a score 1 unit
higher than that calculated by an assay that yields slightly lower
results.
Of importance, our scoring system was not developed to
assess the longer term prognosis of patients receiving HAART
and thus should not be used as an argument against attempts to
achieve optimal virus control. Complete virus control is indeed
likely to be important to avoid the development of resistance
[38, 39], which, in the longer term, probably limits the durability
of response of the antiretroviral regimen that the patient is cur-
rently receiving. However, our results support the hypothesis
that, as long as the CD4 cell count increases after the initiation
of HAART, the patient is achieving some clinical benefit from
therapy, even if the virus load is not totally suppressed [40, 41].
Previously, we [26] and others [42–44] reported the prognos-
tic applications of the hemoglobin level. The grading of anemia
used in the current analysis is similar to that described elsewhere
by the EuroSIDA group [26]. The mechanism by which hemo-
globin level is such a strong predictor of clinical prognosis
remains to be determined. It is well known that the hemopoiesis
of persons with severe infections is impaired. Therefore, patients
with an ongoing illness that has not yet manifested itself as a
AIDS-defining event (and thus is not counted as an end point in
Table 4. Incidence of clinical progression: derivation and validation cohorts.
Score
EuroSIDA derivation cohort EuroSIDA validation cohort Barcelona validation cohort
Incidence 95% CI
Events/
person-years Incidence 95% CI
Events/
person-years Incidence 95% CI
Events/
person-years
0 1.4 0.9–2.0 26/1819 0.5 0.2–1.0 7/1437 0.8 0.3–2.0 5/589
1 1.6 0.7–2.9 10/623 1.5 0.5–3.2 6/405 1.5 0.3–4.4 3/200
2 1.8 1.0–2.5 19/1083 2.0 1.2–3.2 17/858 2.7 1.2–5.1 9/335
3 2.0 0.9–3.7 9/456 3.7 2.1–6.0 16/433 4.7 1.9–9.7 7/148
4 5.7 3.4–9.0 19/334 3.9 1.9–7.1 10/259 2.7 0.5–7.9 3/111
5 7.6 4.9–10.4 29/380 6.6 4.1–9.1 27/410 5.7 2.5–11.3 8/140
6 12.7 7.1–20.9 15/118 12.9 6.8–22.0 13/101 7.5 1.5–22.0 3/40
7 11.6 7.0–16.2 24/207 17.9 11.6–24.2 31/173 15.4 7.4–28.3 10/65
8 25.0 3.0–90.3 2/8 6.7 0.2–37.1 1/15 0.0 0.0–368.9 0/1
9 26.9 14.7–45.2 14/52 30.9 18.0–49.5 17/55 5.5 0.1–20.5 1/18
10 41.2 15.6–80.0 7/18 6.3 1.3–23.1 1/16 200.0 24.0–723.0 2/1
11 40.8 26.0–55.7 29/71 39.7 25.8–53.7 31/78 70.0 40.0–100.0 21/30
>12 66.7 8.0–240.0 2/3 300.0 110.0–655.0 6/2 100.0 12.0–360.0 2/2
RR/unit highera 1.39 1.34–1.44 1.43 1.38–1.48 1.46 1.38–1.55
RH/higherb 1.38 1.33–1.43 1.41 1.36–1.46 1.43 1.35–1.52
NOTE. CI, confidence interval; RH, relative hazard; RR, rate ratio.
a Increased rate of clinical progression associated with single unit increase in score estimated from Poisson regression.
b Increased RH of clinical progression associated with single unit increase in score estimated by fitting score as time-updated covariate in a Cox proportional hazards
model.
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our analysis) may have a tendency to develop anemia. If so, ane-
mia may act as a marker of ongoing, albeit undiagnosed, oppor-
tunistic disease. The reduction in size of the RHs with increasing
lag time is consistent with this. Alternatively, anemia may be a
marker of general immune activation that is associated with the
progression of the HIV infection [45]. Any clinical benefit over
and above symptomatic relief of the symptoms caused by the
anemia, by correction of anemia by blood transfusion or other
treatment (e.g., erythropoietin), should be examined in random-
ized controlled trials.
Several pre-HAART era studies identified the large variabil-
ity in prognosis (even after adjustment for variations in level of
immunodeficiency) for different AIDS-defining events [17, 25].
The 2 diseases with the poorest survival rate were consistently
PML and NHL. Therefore, we considered these diagnoses sepa-
rately from all other AIDS-defining illnesses. Of interest, the
presence of either of these 2 illnesses resulted in an increased
score, but no other AIDS-defining illnesses did so. In this way,
the scoring of patients as they start HAART allows for recovery
from a previous nonserious opportunistic infection without add-
ing clinically prognostic information once HAART is initiated.
As would be expected, we found that the predictive ability of
the score was substantially inferior if it was based only on vari-
ables available at the time of initiation of HAART (data not
shown). We also investigated other potentially prognostic vari-
ables such as time receiving HAART (to assess whether the
score remains clinically useful as time on HAART increases) or
starting a new antiretroviral. After adjustment for changes in
the CD4 cell count, level of anemia, and virus load, these poten-
tially important variables were no longer independently predic-
tive, although this should continue to be evaluated with more fol-
low-up. The variables of CD4 cell count, hemoglobin level, and
clinical status were also highly predictive of clinical disease pro-
gression before the introduction of HAART. There were insuffi-
cient data on virus load from this time period for comment. It
should also be noted that some patients interrupt HAART for a
period of time. We could not evaluate whether the clinical risk
associated with a given score value remained the same in people
who were not receiving therapy. In the absence of such evidence,
it seems most prudent to assume that the clinical risk estimates
that we have provided apply only to those continuing to receive
HAART.
Our scoring system is, as are most others, a simplification of
the information on which it is based. The score was intentionally
constructed in a way that makes it easy to remember and
implement in clinical practice. Ultimately, assessing the labora-
tory markers as continuous log-transformed variables provided
the best predictor of clinical progression but would be difficult
to use. Some arbitrary cutoffs of the laboratory markers were
therefore needed. These were decided before the initiation of
this analysis, on the basis of previously reported studies and
commonly used cutoffs. However, such a simplification can be
criticized. For example, a patient with several CD4 cell counts
in the range of 55–90 cells/mm3 over the past year now has a
cell count of 49 cells/mm3, which adds 4 score points to his over-
all score. This may be an indicator of disease progression, par-
ticularly if subsequent measurements are consistent, but it may
also be due to assay variations. Updating the score with the next
available laboratory data will help to confirm whether the patient
was at an increased risk of clinical progression. Furthermore, a
patient with, for example, a CD4 cell count of 49 cells/mm3
does not carry exactly the same risk as a person with a CD4 cell
Figure 1. Incidence (95% confidence intervals) of clinical progression (new AIDS-defining event or death) for each value of the score in persons
starting highly active antiretroviral therapy. Data are combined from 3 cohorts (see table 3; 5415 persons). Also shown are number of events and
person-years of follow-up on which incidence estimates are based.
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count of ,5 cells/mm3. Clearly, clinical judgment should be
used in the interpretation of the results from the score, together
with information from repeated laboratory tests.
There are several other important limitations in the use of this
scoring system. All patients included in the study had started
HAART but not agents that specifically stimulate the immune
system (e.g., interleukin [IL]–2) [46]. It remains to be demon-
strated whether the “quality” of the CD4 cells produced in pe-
ripheral blood with IL-2 are of equal clinical efficacy with those
produced in conjunction with HAART. Other factors, such as
duration of HAART therapy (assessed but not found to be of
importance) or comorbidities (e.g., hepatitis), may influence the
long-term prognosis of patients on HAART, possibly through
inducing late-onset fatal adverse events. The predictability of
the score should be reevaluated as more experience with
HAART accumulates. Also, our score was based mainly on the
use of PIs, rather than NNRTIs, in the HAART regimen. We
found no significant evidence for differences in the incidence of
clinical disease for different score values for patients taking
NNRTI-based HAART regimens, but this remains a possibility.
Furthermore, the results should be extrapolated with caution to
areas of the world where the HIV-related disease pattern and
causes of death differ from those observed here. For example,
persons who start HAART in Southeast Asia and Africa may be
at substantially higher risk of specific AIDS-defining illnesses,
such as tuberculosis. Thus, other prognostic variables may be
more important in those areas, and there may be population-
based differences in hemoglobin levels. Finally, most patients
included in our analysis received appropriate disease-specific
prophylaxis based on current guidelines [47] (e.g., 85% of pa-
tients with CD4 cell counts,200 cells/mm3 had prophylaxis to
prevent the development of P. carinii pneumonia), and, hence,
application of the score on other populations assumes that these
guidelines are followed.
There are several situations in which this scoring system could
be used. On a population basis, the score would characterize the
health status of a group of patients on HAART for use in compar-
ison with other cohorts and would assess changes in the risk of
clinical progression over time. For individual patients receiving
HAART under routine care, the score could be used to identify
patients who are at highest risk of clinical disease progression.
EuroSIDA Study Group Members
Members of the multicenter EuroSIDA study group are as fol-
lows (names of national coordinators are in italics): Austria:
N. Vetter (Pulmologisches Zentrum der Stadt, Vienna); Bel-
gium: N. Clumeck, P. Hermans, and B. Sommereijns (Saint-
Pierre Hospital, Brussels) and R. Colebunders (Institute of Trop-
ical Medicine, Antwerp); Czech Republic: L. Machala and
H. Rozsypal (Faculty Hospital Bulovka, Prague); Denmark:
J. Nielsen, J. Lundgren, T. Benfield, and O. Kirk (Hvidovre Hos-
pital, Copenhagen), J. Gerstoft, T. Katzenstein, B. Røge, and
P. Skinhøj (Rigs-Hospitalet, Copenhagen), and C. Pedersen
(Odense University Hospital, Odense); France: C. Katlama and
C. Rivie`re (Hoˆpital de la Pitie´-Salpe´tie`re, Paris), J.-P. Viard
(Hoˆpital Necker-Enfants Malades, Paris), T. Saint-Marc (Hoˆpi-
tal Edouard Herriot, Lyon), P. Vanhems (University Claude
Bernard, Lyon), and C. Pradier (Hoˆpital de l’Archet, Nice);
Germany: M. Dietrich and C. Manegold (Bernhard-Nocht-
Institut for Tropical Medicine, Hamburg), J. van Lunzen
(Eppendorf Medizinische Kernklinik, Hamburg), V. Miller and
S. Staszewski (J. W. Goethe University Hospital, Frankfurt),
F.-D. Goebel (Medizinische Poliklinik, Munich), and Bernd
Salzberger (Universita¨t Ko¨ln, Cologne); Greece: J. Kosmidis,
P. Gargalianos, and H. Sambatakou (Athens General Hospital,
Athens) and G. Panos, G. Boulmetis, and M. Astriti (1st IKA
Hospital, Athens); Hungary: D. Banhegyi (Szent La´slo´ Hospital,
Budapest); Ireland: F. Mulcahy (St. James’s Hospital, Dublin);
Israel: I. Yust and D. Turner (Ichilov Hospital, Tel Aviv),
S. Pollack and Z. Ben-Ishai (Rambam Medical Center, Haifa),
Z. Bentwich (Kaplan Hospital, Rehovot), and S. Maayan
(Hadassah University Hospital, Jerusalem); Italy: S. Vella and
A. Chiesi (Istituto Superiore di Sanita, Rome), V. Vullo and
P. Santopadre (Universita` di Roma La Sapienza, Rome),
C. Arici, P. Franci, P. Narciso, A. Antinori, and M. Zaccarelli
(Ospedale Spallanzani, Rome), F. Suter and A. Cremaschi
(Ospedale Riuniti, Bergamo), R. Pristera´ (Ospedale Generale
Regionale, Bolzano), F. Mazzotta and F. Vichi (Ospedale
S. Maria Annunziata, Florence), B. DeRienzo and A. Bedini
(Universita` di Modena, Modena), A. Chirianni and E.
Montesarchio (Presidio Ospedaliero AD Cotugno, Naples),
A. Lazzarin and R. Finazzi (Ospedale San Raffaele, Milan), and
A. D’Arminio Monforte (Ospedale L. Sacco, Milan); Luxem-
bourg: R. Hemmer and T. Staub (Centre Hospitalier); The
Netherlands: P. Reiss (Academisch Medisch Centrum bij de
Universiteit van Amsterdam, Amsterdam); Norway: J. Bruun
and A. Maeland (Ulleva˚l Hospital, Oslo); Poland: B. Knysz and
J. Gasiorowski (Medical University, Wroslaw), A. Horban
(Centrum Diagnostyki i Terapii AIDS, Warsaw), R. Rogowska-
Szadkowska (Medical University, Bialystok), A. Boron-
Kaczmarska (Medical Univesity, Szczecin), M. Beniowski
(Osrodek Diagnostyki i Terapii AIDS, Chorzow), and H. Trocha
(Medical University, Gdansk); Portugal: F. Antunes (Hospital
Santa Maria, Lisbon), K. Mansinho (Hospital de Egas Moniz,
Lisbon), and R. Proenca (Hospital Curry Cabral, Lisbon); Spain:
J. Gonza´lez-Lahoz, R. Polo, and V. Soriano (Hospital Carlos III,
Madrid), B. Clotet, A. Jou, J. Conejero, and C. Tural (Hos-
pital Germans Trias i Pujol, Badalona), and J. M. Gatell and J. M.
Miro´ (Hospital Clinic i Provincial, Barcelona); Sweden:
A. Blaxhult (Karolinska Hospital, Stockholm), P. Pehrson (Hud-
dinge Sjukhus, Stockholm), and B. Heidemann (So¨dersjukhuset,
Stockholm); Switzerland: B.Ledergerber andR. Weber (Univer-
sity Hospital, Zurich), P. Francioli and A. Telenti (Centre Hos-
pitalier Universitaire Vaudois, Lausanne) and B. Hirschel and V.
Soravia-Dunand (Hospital Cantonal Universitaire, Geneva);
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United Kingdom: S. Barton (St. Stephen’s Clinic, Chelsea, and
Westminster Hospital, London), A. M. Johnson and D. Mercey
(Royal Free and University College London Medical School
University College Campus, London), A. Phillips, C. Loveday,
M. A. Johnson, and A. Mocroft (Royal Free and University
College Medical School Royal Free Campus, London), A.
Pinching and J. Parkin (Medical College of Saint Bartholo-
mew’s Hospital, London), J. Weber and G. Scullard (Imperial
College School of Medicine at St. Mary’s, London), M. Fisher
(Royal Sussex County Hospital, Brighton), and R. Brettle (City
Hospital, Edinburgh).
Steering committee. J. Nielsen (chair), N. Clumeck, M.
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